Johnson & Johnson (JNJ): who owns it and who trades it
As of Nov 16, 2026, JNJ insiders reported 29 open-market sales worth $154M and 1 purchase worth $258K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Joaquin Duato (CEO), with $66.8M. 10 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Johnson & Johnson
From the latest filingsOverall: more selling than buying. Insiders and Congress mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns JNJ
4,651 funds and institutions reported JNJ shares worth $456B at the end of Q2 2026, about 75% of the company. The largest holder is BlackRock, Inc. with 8.8%.
Funds and institutions (13F) 75%Everyone else 25%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 212.10M | 8.81% | $53.9B | -1% |
| Vanguard Capital Management LLC | 157.23M | 6.53% | $39.9B | +0% |
| State Street Corp | 133.78M | 5.56% | $34B | +0% |
| Vanguard Portfolio Management LLC | 64.37M | 2.67% | $16.3B | +1% |
| Geode Capital Management, LLC | 59.09M | 2.45% | $15B | -0% |
| JPMorgan Chase & Co | 58.30M | 2.42% | $15.1B | – |
| Morgan Stanley | 44.81M | 1.86% | $11.4B | +0% |
| Norges Bank | 31.83M | 1.32% | $8.1B | – |
| State Farm Mutual Automobile Insurance Co | 31.59M | 1.31% | $8B | No change |
| Northern Trust Corp | 28.79M | 1.20% | $7.3B | -2% |
| Bank of America Corp | 23.44M | 0.97% | $6B | -8% |
| T. Rowe Price Associates | 23.00M | 0.96% | $5.8B | +39% |
| FMR LLC (Fidelity) | 22.60M | 0.94% | $5.7B | -9% |
| Wellington Management Group LLP | 22.59M | 0.94% | $5.7B | +13% |
| Bank of New York Mellon Corp | 21.68M | 0.90% | $5.5B | -1% |
| Goldman Sachs Group Inc | 19.72M | 0.82% | $5B | +9% |
| Legal & General Group Plc | 19.29M | 0.80% | $4.9B | -0% |
| Charles Schwab Investment Management Inc | 19.13M | 0.79% | $4.9B | -0% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 18.42M | 0.77% | $4.7B | -6% |
| Wells Fargo & Company | 17.37M | 0.72% | $4.4B | +3% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, JNJ insiders reported $258K of open-market purchases and $154M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Elizabeth Forminard | Vice president | Sale | 13,072 | $284.39 | $3.7M | Form 4 |
| Sep 2, 2026 | Timothy Schmid | Vice president | Sale | 22,527 | $274.74 | $6.2M | Form 4 |
| Sep 2, 2026 | Timothy Schmid | Vice president | Sale | 11,070 | $274.74 | $3M | Form 4 |
| Aug 17, 2026 | Jennifer L Taubert | Vice president | Sale | 15,000 | $263.36 | $4M | Form 4 |
| Aug 13, 2026 | Joaquin Duato | CEO | Sale | 20,976 | $262.00 | $5.5M | Form 4 |
| Aug 13, 2026 | Joaquin Duato | CEO | Sale | 102,315 | $261.00 | $26.7M | Form 4 |
| Aug 6, 2026 | Elizabeth Forminard | Vice president | Sale | 6,574 | $255.93 | $1.7M | Form 4 |
| Aug 6, 2026 | Elizabeth Forminard | Vice president | Sale | 9,344 | $257.76 | $2.4M | Form 4 |
| Aug 5, 2026 | Joaquin Duato | CEO | Sale | 41,957 | $258.06 | $10.8M | Form 4 |
| Aug 5, 2026 | Joaquin Duato | CEO | Sale | 6,523 | $258.74 | $1.7M | Form 4 |
| Jul 20, 2026 | Vanessa Broadhurst | Vice president | Sale | 23,054 | $251.27 | $5.8M | Form 4 |
| Jun 11, 2026 | Kathryn E Wengel | Vice president | Sale | 10,000 | $241.15 | $2.4M | Form 4 |
| Feb 27, 2026 | Robert J Decker | Vice president | Sale | 4,075 | $247.87 | $1M | Form 4 |
| Feb 20, 2026 | Timothy Schmid | Vice president | Sale | 1,322 | $245.66 | $325K | Form 4 |
| Feb 18, 2026 | Timothy Schmid | Vice president | Sale | 8,998 | $244.53 | $2.2M | Form 4 |
| Feb 18, 2026 | Timothy Schmid | Vice president | Sale | 13,625 | $244.20 | $3.3M | Form 4 |
| Feb 17, 2026 | James D. Swanson | Vice president | Sale | 20,521 | $242.70 | $5M | Form 4 |
| Feb 17, 2026 | Joseph J Wolk | CFO | Sale | 19,241 | $242.99 | $4.7M | Form 4 |
| Feb 17, 2026 | Joseph J Wolk | CFO | Sale | 24,961 | $242.68 | $6.1M | Form 4 |
| Feb 17, 2026 | Joseph J Wolk | CFO | Sale | 33,386 | $242.75 | $8.1M | Form 4 |
| Feb 17, 2026 | Joseph J Wolk | CFO | Sale | 12,066 | $242.87 | $2.9M | Form 4 |
| Feb 17, 2026 | John C Reed | Vice president | Sale | 29,927 | $243.00 | $7.3M | Form 4 |
| Feb 17, 2026 | John C Reed | Vice president | Sale | 2,283 | $243.00 | $555K | Form 4 |
| Feb 17, 2026 | John C Reed | Vice president | Sale | 21,721 | $243.00 | $5.3M | Form 4 |
| Feb 17, 2026 | Vanessa Broadhurst | Vice president | Sale | 6,197 | $243.39 | $1.5M | Form 4 |
| Feb 13, 2026 | James D. Swanson | Vice president | Sale | 19,368 | $243.76 | $4.7M | Form 4 |
| Feb 13, 2026 | James D. Swanson | Vice president | Sale | 22,191 | $243.71 | $5.4M | Form 4 |
| Jan 26, 2026 | Joaquin Duato | CEO | Sale | 48,782 | $221.48 | $10.8M | Form 4 |
| Jan 26, 2026 | Joaquin Duato | CEO | Sale | 51,218 | $220.99 | $11.3M | Form 4 |
| Nov 26, 2025 | John G Morikis | Director | Purchase | 1,250 | $206.15 | $258K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Joaquin Duato | CEO and Chairman of the Board, Director | – | $66.8M | Aug 13, 2026 |
| Joseph J Wolk | Exec VP, CFO | – | $21.8M | Feb 17, 2026 |
| James D. Swanson | EVP, CIO | – | $15.1M | Feb 17, 2026 |
| Timothy Schmid | EVP, WW Chair, MedTech | – | $15.1M | Sep 2, 2026 |
| John C Reed | EVP, Innovative Medicine, R&D | – | $13.1M | Feb 17, 2026 |
| Elizabeth Forminard | EVP, Chief Legal Officer | – | $7.8M | Nov 12, 2026 |
| Vanessa Broadhurst | EVP, Global Corp Affairs | – | $7.3M | Jul 20, 2026 |
| Jennifer L Taubert | EVP, WWC. Innovative Medicine | – | $4M | Aug 17, 2026 |
| Kathryn E Wengel | EVP, Chief TO and Risk Officer | – | $2.4M | Jun 11, 2026 |
| Robert J Decker | VP Corporate Controller | – | $1M | Feb 27, 2026 |
| John G Morikis | Director | $258K | – | Nov 26, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
JNJ short interest
Low short interest. 0.7% of JNJ shares are sold short: about 1 share in 141. Over the last 12 reports the number of shares short went down 26%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 17.07M JNJ shares were sold short, 0.7% of the shares outstanding, up 1.8% from the report before. At the average daily volume of 7.09M shares, buying them all back would take about 2.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 17.07M | 0.71% | +2% | 7.09M | 2.4 |
| Oct 15, 2026 | 16.77M | 0.70% | -24% | 8.52M | 2.0 |
| Sep 30, 2026 | 22.07M | 0.92% | +4% | 6.75M | 3.3 |
| Sep 15, 2026 | 21.19M | 0.88% | -2% | 5.81M | 3.6 |
| Aug 31, 2026 | 21.67M | 0.90% | +0% | 6.55M | 3.3 |
| Aug 14, 2026 | 21.59M | 0.90% | -15% | 6.48M | 3.3 |
| Jul 31, 2026 | 25.41M | 1.05% | -7% | 8.50M | 3.0 |
| Jul 15, 2026 | 27.43M | 1.14% | +3% | 7.47M | 3.7 |
| Jun 30, 2026 | 26.58M | 1.10% | -0% | 10.72M | 2.5 |
| Jun 15, 2026 | 26.69M | 1.11% | +14% | 7.40M | 3.6 |
| May 29, 2026 | 23.41M | 0.97% | +2% | 7.94M | 3.0 |
| May 15, 2026 | 23.04M | 0.96% | +3% | 7.54M | 3.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded JNJ
Since Nov 17, 2024, 22 members of Congress reported 25 purchases and 34 sales of JNJ. The latest was a sale by Thomas H. Kean, Jr. on Sep 30, 2026, reported Oct 30, 2026.
Purchases 25Sales 34
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Thomas H. Kean, Jr. (R-NJ) | Partial sale | $1K–$15K | Self | Oct 30, 2026 | Report |
| Sep 8, 2026 | Lloyd Doggett (D-TX) | Purchase | $1K–$15K | Self | Oct 5, 2026 | Report |
| Aug 27, 2026 | Thomas H. Kean, Jr. (R-NJ) | Partial sale | $1K–$15K | Self | Sep 12, 2026 | Report |
| Aug 20, 2026 | John Boozman (R-AR) | Partial sale | $1K–$15K | Joint | Sep 11, 2026 | Report |
| Jul 30, 2026 | Richard McCormick (GA) | Sale | $1K–$15K | Self | Aug 14, 2026 | Report |
| Jun 29, 2026 | Thomas H. Kean, Jr. (R-NJ) | Partial sale | $1K–$15K | Self | Jul 15, 2026 | Report |
| Jun 9, 2026 | Lloyd Doggett (D-TX) | Purchase | $1K–$15K | Self | Jul 6, 2026 | Report |
| Jun 2, 2026 | Thomas H. Kean, Jr. (R-NJ) | Partial sale | $1K–$15K | Self | Jul 15, 2026 | Report |
| Mar 30, 2026 | Alan Armstrong (R-OK) | Purchase | $1K–$15K | Self | Jul 21, 2026 | Report |
| Mar 27, 2026 | Alan Armstrong (R-OK) | Purchase | $15K–$50K | Self | Jul 21, 2026 | Report |
| Mar 26, 2026 | Thomas H. Kean, Jr. (R-NJ) | Partial sale | $1K–$15K | Self | Apr 13, 2026 | Report |
| Mar 19, 2026 | John Boozman (R-AR) | Partial sale | $1K–$15K | Joint | Apr 14, 2026 | Report |
| Mar 19, 2026 | Richard McCormick (GA) | Partial sale | $1K–$15K | Self | Apr 7, 2026 | Report |
| Mar 10, 2026 | Lloyd Doggett (D-TX) | Purchase | $1K–$15K | Self | Apr 6, 2026 | Report |
| Jan 23, 2026 | Thomas H. Kean, Jr. (R-NJ) | Partial sale | $15K–$50K | Self | Feb 19, 2026 | Report |
| Dec 18, 2025 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | Jan 15, 2026 | Report |
| Dec 9, 2025 | Lloyd Doggett (D-TX) | Purchase | $1K–$15K | Self | Jan 2, 2026 | Report |
| Nov 20, 2025 | Thomas H. Kean, Jr. (R-NJ) | Partial sale | $15K–$50K | Self | Dec 19, 2025 | Report |
| Nov 13, 2025 | Julie Johnson (D-TX) | Partial sale | $1K–$15K | Joint | Dec 11, 2025 | Report |
| Nov 5, 2025 | Richard McCormick (GA) | Purchase | $1K–$15K | Self | Dec 9, 2025 | Report |
| Oct 31, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 30, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 30, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 10, 2025 | Jared Moskowitz (D-FL) | Partial sale | $1K–$15K | Child | Nov 22, 2025 | Report |
| Sep 23, 2025 | Val T. Hoyle (D-OR) | Sale | $1K–$15K | Spouse | Oct 10, 2025 | Report |
| Aug 19, 2025 | Kelly Morrison (D-MN) | Partial sale | $1K–$15K | Self | Sep 11, 2025 | Report |
| Aug 14, 2025 | Julie Johnson (D-TX) | Partial sale | $1K–$15K | Joint | Sep 11, 2025 | Report |
| Aug 4, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Sep 12, 2025 | Report |
| Jul 31, 2025 | Thomas H. Kean, Jr. (R-NJ) | Partial sale | $15K–$50K | Self | Aug 20, 2025 | Report |
| Jun 24, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 17, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 16, 2025 | Scott Franklin (R-FL) | Sale | $15K–$50K | Joint | Jul 14, 2025 | Report |
| Jun 12, 2025 | Pete Sessions (R-TX) | Sale | $15K–$50K | Spouse | Jun 21, 2025 | Report |
| Jun 10, 2025 | Lloyd Doggett (D-TX) | Purchase | $1K–$15K | Self | Jul 7, 2025 | Report |
| May 30, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $15K–$50K | Self | Jun 6, 2025 | Report |
| May 12, 2025 | Jefferson Shreve (R-IN) | Sale | $50K–$100K | Self | Jun 22, 2025 | Report |
| May 5, 2025 | Marjorie Greene (GA) | Purchase | $1K–$15K | Self | May 6, 2025 | Report |
| Apr 29, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | May 6, 2025 | Report |
| Apr 21, 2025 | Bruce Westerman (R-AR) | Sale | $1K–$15K | Self | May 12, 2025 | Report |
| Apr 9, 2025 | Josh Gottheimer (D-NJ) | Partial sale | $1K–$15K | Joint | May 14, 2025 | Report |
| Apr 8, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Self | Apr 28, 2025 | Report |
| Apr 1, 2025 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | May 14, 2025 | Report |
| Mar 31, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $15K–$50K | Self | Apr 7, 2025 | Report |
| Mar 24, 2025 | George Whitesides (D-CA) | Sale | $100K–$250K | Self | Apr 23, 2025 | Report |
| Mar 19, 2025 | Sheri Biggs (R-SC) | Sale | $15K–$50K | Spouse | Oct 5, 2025 | Report |
| Mar 7, 2025 | Josh Gottheimer (D-NJ) | Partial sale | $1K–$15K | Joint | Apr 10, 2025 | Report |
| Mar 5, 2025 | Jefferson Shreve (R-IN) | Purchase | $15K–$50K | Self | Apr 11, 2025 | Report |
| Mar 4, 2025 | Lloyd Doggett (D-TX) | Purchase | $1K–$15K | Self | Apr 7, 2025 | Report |
| Mar 3, 2025 | Bruce Westerman (R-AR) | Purchase | $1K–$15K | Self | Apr 16, 2025 | Report |
| Feb 24, 2025 | Jefferson Shreve (R-IN) | Purchase | $15K–$50K | Self | Mar 9, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Johnson & Johnson company events
Johnson & Johnson filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 13, 2026.
- Oct 13, 2026ResultsReleased financial results. Filing
- Aug 4, 2026LeadershipThe Company announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee effective September 1, 2026. Filing
- Jul 29, 2026AnnouncementShared information with investors. Filing
- Jul 28, 2026AnnouncementShared information with investors. Filing
- Jul 15, 2026ResultsReleased financial results. Filing
- Apr 28, 2026VoteReported shareholder vote results. Filing
- Apr 14, 2026AnnouncementJohnson & Johnson issued the attached press release (Exhibit 99.3) announcing that its Board of Directors declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases. Filing
- Jan 21, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
How Johnson & Johnson makes money
Innovative Medicine brought in 64% of Johnson & Johnson's revenue ($60.4B of $94.2B) in 2025. MedTech was next, at 36%.
By business segment, 2025
By region, 2025
From Johnson & Johnson's annual report (10-K) for the year ended Dec 28, 2025, filed Feb 11, 2026. The company chooses how to group its revenue, so the parts differ from one company to the next. Read the filing · How the biggest companies make money
Johnson & Johnson financials
Famous investors that hold JNJ
10 of the 50 well-known investors we track reported holding JNJ in their latest 13F filing. The largest position is Ken Fisher's, worth $3.9B.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 14.84M | $3.9B | 1.1% | +11% |
| Jeremy Grantham · GMO | Q3 2026 | 6.96M | $1.8B | 4.0% | -2% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.74M | $726M | 0.4% | +83% |
| Tom Gayner · Markel Group | Q3 2026 | 610,800 | $162M | 1.3% | No change |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 547,531 | $145M | 0.6% | -18% |
| Israel Englander · Millennium Management | Q3 2026 | 109,905 | $29.1M | 0.0% | -82% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 37,876 | $10M | 0.0% | New |
| George Soros · Soros Fund Management | Q3 2026 | 34,019 | $9M | 0.2% | No change |
| Tom Russo · Gardner Russo & Quinn | Q3 2026 | 1,112 | $294K | 0.0% | No change |
| Bill Nygren · Harris Associates (Oakmark) | Q3 2026 | 858 | $227K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Johnson & Johnson (JNJ) stock
Who owns the most JNJ stock?
The largest reported owner of Johnson & Johnson (JNJ) is BlackRock, Inc., with 8.8% of the company. In total, 4,651 funds and institutions reported holding JNJ at the end of Q2 2026, together about 75% of the shares. See the largest owners.
Are JNJ insiders buying or selling?
In the last 12 months, JNJ insiders reported 1 open-market purchase worth $258K and 29 sales worth $154M. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in JNJ?
As of Oct 30, 2026, 17.07M JNJ shares were sold short, 0.7% of the shares outstanding, up 1.8% from the report before. At the average daily volume of 7.09M shares, buying them all back would take about 2.4 trading days (days to cover). See the history.
Have members of Congress traded JNJ?
Yes. 22 members of Congress reported 25 purchases and 34 sales of JNJ since Nov 17, 2024. The latest was reported on Oct 30, 2026. See the trades.
How does Johnson & Johnson make money?
Innovative Medicine brought in 64% of Johnson & Johnson's revenue ($60.4B of $94.2B) in 2025. MedTech was next, at 36%. See the full split.
Which famous investors hold JNJ?
10 of the 50 well-known investors we track reported JNJ in their latest 13F filing, including Ken Fisher, Jeremy Grantham, Ken Griffin. The largest position is worth $3.9B. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.